Seattle Genetics (SGEN) Announces FDA Granted Breakthrough Therapy Designation to ADCETRIS for Frontline Peripheral T-Cell Lymphomas
November 15, 2018 8:02 AM
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
